/GOSS
GOSS Stock - Gossamer Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$3.44+0.29%
+$0.01 (+0.29%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.43
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+161.6%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GOSS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.41 – $3.47
TARGET (TP)$9.00
STOP LOSS$3.16
RISK/REWARD1:19.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.92
52W High$3.87
52W Low$0.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $114.70M | N/A | N/A | N/A | N/A |
| Gross Profit | $114.70M | N/A | N/A | N/A | $-4,268,000 |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-59,919,000 | $-183,759,000 | $-218,593,000 | $-216,124,000 | $-210,582,000 |
| Net Income | $-56,528,000 | $-179,817,000 | $-229,378,000 | $-234,004,000 | $-243,360,000 |
| Net Margin | -49.3% | N/A | N/A | N/A | N/A |
| EPS | $-0.25 | $-0.80 | $-2.84 | $-3.33 | $-3.67 |
Company Overview
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
62%
Hold / Neutral
5
38%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
8 Bullish5 Neutral/Bearish
Price Targets
$12
Average Target
↑ 239.8% Upside
Now
$1
Low
$12
Average
$24
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 10th 2025 | UBS | Upgrade | Buy | $9 |
| July 14th 2025 | Scotiabank | Initiation | Sector Outperform | $11 |
| June 25th 2024 | Oppenheimer | Initiation | Outperform | $9 |
| April 5th 2024 | Wedbush | Resumed | Outperform | $4 |
| July 27th 2023 | UBS | Downgrade | Neutral | $1.25← $8 |
| March 7th 2023 | Raymond James | Downgrade | Market Perform | - |
| March 1st 2023 | Guggenheim | Initiation | Neutral | - |
| December 7th 2022 | JP Morgan | Downgrade | Underweight | - |
| December 7th 2022 | SMBC Nikko | Downgrade | Neutral | $3 |
| December 7th 2022 | Barclays | Downgrade | Equal Weight | $2← $18 |
| October 20th 2022 | Goldman | Initiation | Buy | $22 |
| September 21st 2022 | JP Morgan | Initiation | Neutral | $17 |
| September 19th 2022 | Wedbush | Initiation | Outperform | $24 |
| April 18th 2022 | Raymond James | Initiation | Outperform | $19 |
| April 6th 2022 | UBS | Initiation | Buy | $19 |
Earnings History & Surprises
GOSSBeat Rate
53%
Last 19 quarters
Avg Surprise
+1.7%
EPS vs Estimate
Beats / Misses
10/7
2 met exactly
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q1 24
-5.0%
$-0.21vs$-0.20
Q2 24
0.0%
$-0.19vs$-0.19
Q3 24
-4.3%
$0.22vs$0.23
Q4 24
+22.2%
$-0.14vs$-0.18
Q1 25
+11.8%
$-0.15vs$-0.17
Q2 25
+11.1%
$-0.16vs$-0.18
Q3 25
+5.6%
$-0.17vs$-0.18
Q4 25
-10.5%
$-0.21vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 12, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.19 | $-0.21 | -10.5% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.18 | $-0.17 | +5.6% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.17 | $-0.15 | +11.8% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $0.23 | $0.22 | -4.3% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.19 | $-0.19 | 0.0% | = MET |
Q1 2024 | Mar 5, 2024 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.49 | $-0.45 | +8.2% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.55 | $-0.52 | +5.5% | ✓ BEAT |
Q1 2023 | Mar 17, 2023 | $-0.62 | $-0.59 | +4.8% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.66 | $-0.65 | +1.5% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.67 | $-0.74 | -10.4% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.77 | $-0.76 | +1.3% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.74 | $-0.74 | 0.0% | = MET |
Q4 2021 | Nov 8, 2021 | $-0.78 | $-0.80 | -2.6% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.77 | $-0.80 | -3.9% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-0.80 | $-0.78 | +2.5% | ✓ BEAT |
Latest News
Gossamer Bio Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $13.294M
📉 NegativeBenzinga•Nov 5, 2025, 09:31 PM
Gossamer Bio Enters into Option Agreement To Acquire Respira Therapeutics And Its Lead Candidate, RT234 For Pulmonary Hypertension; Gossamer To Issue 2.5M Shares In Connection With Signing And Shareholders Will Be Eligible For Milestones
📈 PositiveBenzinga•Sep 25, 2025, 11:32 AM
Gossamer Bio To Present At European Respiratory Society (ERS) Congress 2025 Sept 28 And 30
➖ NeutralBenzinga•Sep 22, 2025, 11:37 AM
Cantor Fitzgerald Reiterates Overweight on Gossamer Bioto Overweight
📈 PositiveBenzinga•Sep 11, 2025, 12:32 PM
Gossamer Bio higher as UBS upgrades on upcoming data catalyst
📈 PositiveSeeking Alpha•Sep 10, 2025, 02:04 PM
Gossamer Bio shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $1.25 to $9.
📈 PositiveBenzinga•Sep 10, 2025, 01:03 PM
UBS Upgrades Gossamer Bio to Buy, Raises Price Target to $9
📈 PositiveBenzinga•Sep 10, 2025, 10:44 AM
Frequently Asked Questions about GOSS
What is GOSS's current stock price?
Gossamer Bio, Inc. (GOSS) is currently trading at $3.44 per share. The stock has moved +0.29% today.
What is the analyst price target for GOSS?
The average analyst price target for GOSS is $9.00, based on 1 analyst.
What sector is Gossamer Bio, Inc. in?
Gossamer Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GOSS's market cap?
Gossamer Bio, Inc. has a market capitalization of $0.78 billion, making it a small-cap company.
Does GOSS pay dividends?
No, Gossamer Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
LXRX
Lexicon Pharmaceuticals, Inc.
$1.17
Mkt Cap: $0.4B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
RIGL
Rigel Pharmaceuticals, Inc.
$41.59
Mkt Cap: $0.7B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
Explore stocks similar to GOSS for comparison